

Review Article

Meta-Analysis of Atrial Fibrillation Ablation in Patients with Systolic Heart Failure

Mohammed Ruzieh ^(b),¹ Andrew J. Foy,¹ Nader M. Aboujamous,² Morgan K. Moroi,³ Gerald V. Naccarelli,¹ Mehrdad Ghahramani,¹ Shaffi Kanjwal,⁴ Joseph E. Marine,⁵ and Khalil Kanjwal ^{(b)⁶}

¹ Penn State Heart and Vascular Institute, Hershey, PA, USA
 ² Penn State Department of Internal Medicine, Hershey, PA, USA
 ³ Penn State College of Medicine, Hershey, PA, USA
 ⁴ St Marys of Michigan, Saginaw, MI, USA
 ⁵ John's Hopkins University School of Medicine, Baltimore, MD, USA
 ⁶ Michigan State University, McLaren Greater Lansing, MI, USA

Correspondence should be addressed to Khalil Kanjwal; khalilkanjwal@yahoo.com

Received 28 October 2018; Revised 3 December 2018; Accepted 16 December 2018; Published 6 January 2019

Academic Editor: Nicholas B. Norgard

Copyright © 2019 Mohammed Ruzieh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Atrial fibrillation (AF) and heart failure (HF) are two common conditions that often coexist and predispose each to one another. AF increases hospitalization rates and overall mortality in patients with HF. The current available therapeutic options for AF in patients with HF are diverse and guidelines do not provide a clear consensus regarding the best management approach. To determine if catheter ablation for AF is superior to medical therapy alone in patients with coexisting HF, we conducted this systematic review and meta-analysis. The primary outcomes evaluated are left ventricular ejection fraction (LVEF), Minnesota Living with Heart Failure Questionnaire (MLWHFQ) scores, 6-minute walk test (6MWT) distance, heart failure hospitalizations, and mortality. The results are presented as a mean difference for continuous outcome measures and odds ratios for dichotomous outcomes (using Mantel-Haenszel random effects model). 7 full texts met inclusion criteria, including 856 patients. AF catheter ablation was associated with a significant increase in LVEF (mean difference 6.8%; 95% CI: 3.5 - 10.1; P<0.001) and 6MWT (mean difference 29.3; 95% CI: 11.8 - 46.8; P = 0.001), and improvement in MLWHFQ (mean difference -12.1; 95% CI: -20.9 - -3.3; P = 0.007). The risk of all-cause mortality was significantly lower in the AF ablation arm (OR 0.49; 95% CI: 0.31 - 0.77; P = 0.002). In conclusion, atrial fibrillation ablation in patients with systolic heart failure is associated with significant improvement in LVEF, quality of life, 6MWT, and overall mortality.

1. Introduction

Atrial fibrillation (AF) and heart failure (HF) are two common conditions that often coexist and can predispose each to one another [1–3]. As the population ages, the prevalence of both conditions is expected to increase. AF increases the risk of stroke, hospitalization from heart failure, length of hospital stay, and overall mortality [4, 5].

The current available therapeutic options for AF in patients with HF are diverse and guidelines do not provide a clear consensus regarding the best approach to management.

The strategy of rhythm control using antiarrhythmic drugs (AADs) is not superior to rate control in patients with both AF and HF [6].

In the last decade, several randomized controlled trials (RCTs) have examined the role of catheter ablation in the AF patient population and have demonstrated improvement in left ventricular function and quality of life [2, 3, 7–11].

To determine if catheter ablation for AF is superior to medical therapy alone in patients with coexisting HF, we performed a meta-analysis of the available RCTs.

2. Methods

We applied the methods recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [12].

2.1. Data Collection and Extraction. We searched PubMed, Google Scholar, the Cochrane Central Register for RCTs and ClinicalTrials.gov for studies that evaluated AF catheter ablation in patients with HF (latest search date: October 1, 2018). The study protocol was drafted by three of the authors (M.R., M.M., and A.F.) and revised by all coauthors. Two authors (M.R. and M.M.) independently reviewed all articles and abstracts for inclusion. They independently extracted information on sample size, follow-up, and outcomes. Discrepancies were discussed and resolved by consensus.

Key search terms used were atrial fibrillation, catheter ablation, pulmonary venous isolation, heart failure, left ventricular dysfunction, low ejection fraction, functional capacity, quality of life, stroke, hospitalization, mortality, and death. Bibliographies of retrieved studies were hand-searched to identify additional relevant studies.

We included studies that randomized patients with AF and systolic HF to either catheter ablation, medical therapy, or atrioventricular-node ablation with pacemaker implantation.

2.2. Outcome and Quality Assessment. The primary outcomes were left ventricular ejection fraction (LVEF), Minnesota Living with Heart Failure Questionnaire (MLWHFQ) scores, 6-minute walk test (6MWT) distance, stroke, heart failure hospitalizations, and mortality. Procedural complications were also summarized.

We used the Cochrane Risk of Bias table and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system, to report risk of bias and quality of study outcomes in each study, respectively.

2.3. Statistical Analysis. The primary analyses were performed using RevMan version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration; Copenhagen, Denmark).

The results are presented as a mean difference for continuous outcome measures (using the inverse variance random effects model) and odds ratios (OR) for dichotomous outcomes (using Mantel-Haenszel random effects model), with 95% confidence interval (CI). We performed sensitivity analyses to ascertain the robustness of the results. We quantified heterogeneity using I², which represents the percentage of variability in the effect risk estimate among studies due to heterogeneity rather than chance (with I² <25% considered as low, I² >75% considered as high, and in between [25% to 75%] as intermediate).

Begg's funnel plots method was used to evaluate for potential publication bias.

A two-sided p-value of <0.05 was considered to be statistically significant.

3. Results

3.1. Qualitative Synthesis. Our search identified 1884 studies, of which 7 full texts met inclusion criteria, Figure 1. A total of 856 patients were included (429 patients randomized to catheter ablation and 427 patients randomized to medical therapy alone), with an average age of 63.4 years and a mean follow-up time of 15.2 months. The proportion of males ranged between 73% and 96%. Mean LVEF was 29.9%. The vast majority of patients had persistent AF, and New York Heart Association (NYHA) Functional Classification II-III. Further patient characteristics are listed in Tables 1 and 2.

3.2. Risks of Bias and Quality Assessment. For all studies there were limitations in methodology and in outcome assessment (per Cochrane and GRADE criteria), Table 3. Randomization was performed using random number generation in all trials and the baseline characteristics for patients in the ablation arm and the control arm were similar. None of the trials had a sham arm and thus patients were not blinded. Outcome assessment, specifically ejection fraction, was blinded in four trials [2, 3, 8, 9]. Based on the GRADE criteria, we have moderate confidence in the outcome estimates derived from the pooled data.

Crossovers and dropouts were described appropriately in all studies. Crossover occurred in two patients in the study by Jones et. al. [3] and in 46 patients in the CASTLE AF trial [11]. However, intention to treat analysis was performed. Loss to follow-up was largest in the CASTLE AF trial at 33 (9.1%) patients (23 [6.3%] in the ablation arm and 10 [2.8%] in the control arm). Further details are provided in Table 4.

Evaluation of the funnel plots revealed no evidence of publication bias.

3.3. Outcomes and Sensitivity Analysis

3.3.1. Arrhythmia Recurrence. AF catheter ablation was an effective therapy and significantly more patients in the AF ablation group were in sinus rhythm at the end of trials (73.7% vs. 18.3%, OR 33.7; 95% CI: 10.2 – 111.7; P< 0.001), Figure 2(a). This difference remained significant when limiting the analysis to the AATAC trial [9] which compared AF ablation to amiodarone, and the CASTLE AF trial [11] which allowed pharmacological rhythm control (71.3% vs. 26.9%, OR 6.4; 95% CI: 3.3 – 12.4; P< 0.001). To achieve this high success rate from AF ablation, repeat intervention was allowed in all trials and the percentage of patients who underwent repeat ablation ranged from 19% to 54%, Table 4.

3.3.2. *LVEF*. Data for LVEF were available from all included trials. There was significant heterogeneity ($I^2 = 90\%$). Our confidence in LVEF outcome estimates derived from pooled data is moderate, since four trials [2, 3, 8, 9] assessed LVEF in a blinded fashion.

Compared to medical therapy alone, AF catheter ablation was associated with a significant increase in LVEF (mean difference 6.8%; 95% CI: 3.5 - 10.1; P<0.001), Figure 2(b). One trial compared AF catheter ablation to AV nodal ablation

	KI	Khan	MacDonald	onald	Jones	es	Hunter	ter	Di Biase	ase	Prabhu	hu	Marrouche	ache
	Ablation	AV ablation /	Ablation	Rate	Ablation	Rate	Ablation	Rate	Ablation	Amiod-	Ablation	rate	Ablation	Medical
	arm	CRT	arm	control	arm	control	arm	control	arm	arone	arm	control	arm	therapy
Mean age (yrs)	60 ± 8	61 ± 8	62.3 ± 6.7	64.4 ± 8.3	64 ± 10	62 ± 9	55 ± 12	60 ± 10	62 ± 10	60 ± 11	59 ± 11	62 ± 9.4	64	64
Female gender	5%	12%	23%	21%	19%	8%	4%	4%	25%	27%	6%	12%	13%	16%
No. of patients	41	40	22	19	26	26	26	24	102	101	33	33	179	184
Follow up (months)	9	9	9.7	6.9	12	12	12	9	24	24	9	9	37.6 ± 20.4	37.4 ± 17.7
Persistent AF	51%	46%	100%	100%	100%	100%	96%	88%	100%	100%	100%	100%	70%	65%
NYHA class	II & III	II & III	II & III	II & III	II & III	II & III	II & III	II & III	II & III	II & III	≥II	≥II	I-IV	I-IV
ICMP	N/A	N/A	50%	47%	38%	27%	23%	29%	62%	65%	%0	%0	40%	52%
NICMP	N/A	N/A	50%	53%	62%	73%	77%	71%	38%	35%	100%	100%	60%	48%
LVEF %	27 ± 8	29 ± 7	36.1 ± 11.9	42.9 ± 9.6	22 ± 8	25 ± 7	31.8 ± 7.7	33.7 ± 12.1	29 ± 5	30 ± 8	32 ± 9.4	34 ± 7.8	32.5	31.5
LA diameter (mm)	49 ± 5	47 ± 6	N/A	N/A	50 ± 6	47 ± 7	52 ± 11	50 ± 10	47 ± 4	48 ± 5	48 ± 6	47 ± 8	48	49.5
6 min walk distance	269 ± 54	281 ± 44	317.5 ± 125.8	351.8 ± 117.1	416 ± 78	411 ± 109	N/A	N/A	348 ± 111	350 ± 130	491 ± 147	489 ± 132	N/A	N/A
Peak VO2	N/A	N/A	N/A	N/A	16.3 ± 5.3	18.2 ± 4.8	N/A	NA	N/A	N/A	N/A	N/A	N/A	N/A
Quality of life	89 ± 12	89 ± 11	55.8 ± 19.8	55.8 ± 19.8 59.2 ± 22.4	42 ± 23	49 ± 21	N/A	N/A	52 ± 24	50 ± 27	N/A	N/A	N/A	N/A

TABLE 1: Characteristics of patients included in the studies.


	Khan	n	MacDonald	nald	Jones	Sč	Hunter	ter	Di	Di Biase	Prabhu	bhu	Marrouche	uche
	Ablation arm	AV ablation/ CRT	Ablation arm	Rate control	Ablation arm	Rate control	Ablation arm	Rate control	Ablation arm	Amiodarone	Ablation arm	rate control	Ablation arm	Medical therapy
Rate control	NA	NA	$\beta B \pm digoxin$	$\beta B \pm digoxin$	$\beta B \pm digoxin$	$\beta B \pm digoxin$	$\beta \mathrm{B}$	$\beta \mathrm{B}$	$\beta B \pm digoxin$	$\beta B \pm digoxin$	$\beta \mathrm{B}$	$\beta \mathrm{B}$	$\beta B \pm digoxin$	$\beta B \pm digoxin$
AAD	5 patients received amio- darone, 4 received class III AAD and 1 received class IC AAD	14 patients received amio- darone and 1 received class III AAD	Oral amio- darone for 3 months in all patients	None	AAD stopped post ablation unless indicated by other reasons	None	AAD stopped post ablation unless indicated by other reasons	None	AAD allowed for 3 months after the first ablation	Amiodarone in all	9 patients received amio- darone and 3 received sotalol	None	45 patients received amio- darone, and 2 received sotalol	56 patients received amio- darone, and 6 received sotalol
Anticoagulation	Warfarin for at least 3 months, then at the discretion of the treating physician	NA	Warfarin Warfarin	Warfarin	N/A	N/A	Warfarin	Warfarin	N/A	N/A	Per guidelines	Per guidelines	Warfarin for at least 6 months, then at the discretion of the treating physician	Per guidelines

0
·=
aj
randomizatio
5

0
Ч
ц
a,
after
after
Ð
60
use
S
<u>_</u>
0
:=
a
.9
5
õ
V
2
2
Э

Cardiovascular Therapeutics





1884 records identified through database and manual search

FIGURE 1: PRISMA diagram showing search strategy results.

with biventricular pacing as a rate control strategy [7], and even when this trial is excluded, AF catheter ablation was still associated with a significant increase in LVEF (mean difference 6.4%; 95% CI: 2.8 – 10.1; P<0.001). Furthermore, when including only trials that had a blinded assessment of LVEF, AF catheter ablation was still associated with an increase in LVEF, although not statistically significant (mean difference 5.3%; 95% CI: -0.6 – 11.2; P = 0.08).

3.3.3. Quality of Life Based on MLWHFQ Scores. Data on MLWHFQ were available from five trials. There was significant heterogeneity ($I^2 = 77\%$). Since patients were not blinded to the intervention, our confidence in the MLWHFQ outcome estimate is low.

There was a significant improvement in the MLWHFQ scores in the AF catheter ablation group when compared to the medical therapy group (mean difference -12.1; 95% CI: -20.9 – -3.3; P = 0.007), Figure 2(c). When excluding the trial that compared AF catheter ablation to AV nodal ablation with biventricular pacing as a rate control strategy, heterogeneity became moderate ($I^2 = 33\%$). However, the mean improvement in the MLWHFQ still favored the AF ablation group (mean difference -8.0; 95% CI: -14.3 – -1.7; P = 0.01).

3.3.4. 6MWT Distance in Meters. Six trials reported 6MWT distance and are included in this analysis. There was significant heterogeneity among these trials ($I^2 = 71\%$).

The mean increase in 6MWT distance was higher in the AF catheter ablation group compared to the medical therapy group (mean difference 29.3; 95% CI: 11.8 - 46.8; P = 0.001), Figure 2(d). When tested for sensitivity, the removal of any individual trial did not appreciably alter the point estimate or confidence interval in the results.

3.3.5. All-Cause Mortality. Every included trial reported allcause mortality on follow-up. However, with the exception of the CASTLE AF trial [11], the trials were not designed nor were they powered to detect a mortality difference. Therefore, our confidence in the outcome estimate derived from pooled data is low.

In addition, there was no heterogeneity ($I^2 = 0.00\%$). The risk of death from any cause was significantly lower in the AF ablation arm (OR 0.49; 95% CI: 0.31 – 0.77; P = 0.002), Figure 2(e). This difference was driven by the CASTLE AF [11] and AATAC trials [9].

Cardiovascular death was only reported by the CASTLE AF trial, and was higher in the medical treatment arm (41 [22.3%] vs. 20 [11.2%]; P = 0.009).

TABLE 3:	Risk o	f bias	assessment table.
----------	--------	--------	-------------------

	TABLE J. KIS	k of bias assessment table.	
Bias	Study	Judgement	Support for judgement
Random sequence generation (selection bias)			
generation (selection bias)	Khan 2008	Low risk	Computer generated
	MacDonald 2011	Low risk	Computer generated
	Jones 2013	Low risk	Computer generated
	Hunter 2014	Low risk	Random number generator
	Di Biase 2016	Low risk	Computer generated
	Prabhu 2017	Low risk	Computer generated
	Marrouche 2018	Low risk	Computer generated
Allocation concealment			Somputer generated
(selection bias)	Khan 2008	Low risk	Commuter concerted and domination
	MacDonald 2011	Low risk	Computer generated randomization
			Computer generated randomization
	Jones 2013	Low risk	Computer generated randomization
	Hunter 2014	Low risk	Random number generator
	Di Biase 2016	Low risk	Computer generated randomization
	Prabhu 2017	Low risk	Computer generated randomization
	Marrouche 2018	Low risk	Computer generated randomization
Blinding of participants and personnel (performance bias)			
,	Khan 2008	High risk	No blinding
	MacDonald 2011	High risk	No blinding
	Jones 2013	High risk	No blinding
	Hunter 2014	High risk	No blinding
	Di Biase 2016	High risk	No blinding
	Prabhu 2017	High risk	No blinding
	Marrouche 2018	High risk	No blinding
Blinding of outcome ssessment (detection bias)		0	
	Khan 2008	High risk	No blinding
	MacDonald 2011	Moderate risk	Only scans analysis was blinded
	Jones 2013	Low risk	People conducting cardiopulmonary exercise test and imaging analysis wer blinded
	Hunter 2014	Moderate risk	Only echocardiogram analysis was blinded
	Di Biase 2016	Moderate risk	Only echocardiogram analysis was blinded
	Prabhu 2017	High risk	No blinding
	Marrouche 2018	High risk	No blinding
ncomplete outcome data addressed (attrition bias)			
	Khan 2008	Low risk	No significant attrition
	MacDonald 2011	Low risk	No significant attrition
	Jones 2013	Low risk	No significant attrition
	Hunter 2014	Low risk	No significant attrition
	Di Biase 2016	Low risk	No significant attrition
	Prabhu 2017	Low risk	No significant attrition
	Marrouche 2018	Low risk	No significant attrition

Cardiovascular Therapeutics

Bias	Study	Judgement	Support for judgement
Selective reporting (reporting bias)			
	Khan 2008	Low risk	
	MacDonald 2011	Low risk	
	Jones 2013	Low risk	
	Hunter 2014	Low risk	
	Di Biase 2016	Low risk	
	Prabhu 2017	Low risk	
	Marrouche 2018	Low risk	

TABLE 3: Continued.

TABLE 4: Intervention and follow up.

	Khan	MacDonald	Jones	Hunter	Di Biase	Prabhu	Marrouche
Frequency of monitoring (months)	3 & 6	3 & 6	3,6 & 12	1, 3 & 6	3, 6, 12 & 24	3 & 6	3, 6, 12, 24, 36, 48 & 60
Method of assessing rhythm	Loop recorder	24h holter monitor	48h holter monitor ± existing implantable devices	48h holter monitor	ECG, and existing implantable devices	24h holter monitor and ILR	Existing implantable devices
Repeat procedure	8 (19.5%)	6 (28.6%)	5 (19.2%)	14 (53.8%)	1.4 ± 0.6 per person	Repeat procedure was allowed (frequency not defined)	37 (24.5%)
Crossover Loss to follow-up	None	None	2	None	None	None	46
	None	3	None	1	None	1	33
Ablation strategy	PVI ± Linear lesions ± left atrial complex fractionated electrograms	PVI ± Linear lesions ± left atrial complex fractionated electrograms ± Cardioversion ± cavotricuspid isthmus ablation	PVI ± Linear lesions ± left atrial complex fractionated electrograms ± Cardioversion ± cavotricuspid isthmus ablation.	PVI ± Linear lesions ± left atrial complex fractionated electrograms ± Cavotricuspid isthmus ablation	PVI, and left atrial posterior wall isolation ± SVC isolation ± Linear lesions ± left atrial complex fractionated electrograms ± cardioversion	PVI, left posterior wall isolation ± cardioversion	PVI, Additional ablation lesions were made at the discretion of the operators

PVI: pulmonary veins isolation and SVC: superior vena cava.

3.3.6. Hospitalizations. HF-related hospitalizations were systematically reported by the AATAC and CASTLE AF trials [9, 11]. Other trials reported procedure related heart failure exacerbations and we summarized this data in the ablation complications section below.

The rare of HF- related hospitalizations was significantly lower in the ablation arm (26.7% vs. 45.1%, OR 0.43; 95% CI: 0.29 - 0.64; P< 0.001), Figure 2(f).


3.3.7. Stroke. This outcome was only systematically reported by the CASTLE AF trial. Other trials reported ablation related stroke and we also summarized this data in the catheter ablation complications section below.


The rate of stroke in the CASTLE AF trial was not significantly lower in the ablation arm compared to the medical treatment arm (5 [3.2%] vs. 11 [6.3%]; P = 0.19).

3.3.8. AF Catheter Ablation Complications. All trials reported complications related to AF catheter ablation. Details of complications and adverse events are listed in Table 5.

There were no procedural related deaths. The overall rate of complications was 33 out of 399 (8.3%), distributed as follows: 2 (0.5%) strokes, 4 (1%) cardiac tamponade, 5 (1.3%) pericardial effusion, 3 (0.8%) pulmonary venous stenosis, 13 (3.3%) access site complications, and 6 (1.5%) heart failure exacerbation.

Study or Subgroup Verits Total Weight M=1, Random, 95% CI M=1, Random, 95% CI MacDonal 2011 10 20 0 18 10.0% 37.00 [1.96, 697.35] 2011 Jones 2013 22 2 2 2 19.16 [1.08, 3257.694] 2011 Jones 2013 19 26 0 24 10.0% 37.00 [1.96, 697.35] 2011 Jones 2013 10 33 33 0 33 6.7% 448.00 [16.84, 2371.27] 2014 Pabhu 2017 33 33 0 33 6.7% 448.00 [16.84, 2371.27] 2014 Marcouche 2018 113 156 40 17.4 24.0% 8.05 [15.2,1,4.19] 2018 Total (95% C) 403 4.16 10.0% 33.76 [10.2,1, 11.165] 10.0 0.00 0.1 0.00 0.1 0.00 0.1 0.00 0.1 0.00 0.1 0.00 0.1 0.00 0.1 0.00 0.1 0.00 0.1 0.00 0.1 <th></th> <th>Abl</th> <th>ation</th> <th>c</th> <th>Control</th> <th></th> <th></th> <th></th> <th>Odds Ratio</th> <th></th> <th></th> <th>Odds Ratio</th> <th></th>		Abl	ation	c	Control				Odds Ratio			Odds Ratio					
$ \frac{k \ln 2008}{ka Cond 2011} = 29 + 41 = 0 + 40 = 10.3\% = 19.1.6 [10.88, 338.82] = 2008 \\ \frac{32001 (10.008)}{32001 (10.68, 697.33)} = 2011 \\ \frac{32001 (10.68, 697.33)}{32001 (10.68, 697.33)} = 2011 \\ \frac{32001 (10.68, 697.33)}{32001 (10.28, 57.64)} = 2013 \\ \frac{33000 (10.28, 57.64)}{3330 (10.28, 57.64)} = 2013 \\ \frac{3300 (10.28, 57.64)}{333 (10.28, 57.64)} = 2013 \\ \frac{3300 (10.28, 57.64)}{333 (10.28, 57.64)} = 2017 \\ \frac{3300 (10.28, 57.64)}{333 (10.28, 57.64)} = 2017 \\ \frac{3300 (10.28, 57.64)}{333 (10.28, 57.64)} = 2018 \\ \frac{3300 (10.28, 57.74)}{333 (10.28, 57.74)} = 0.97, df = 6 (P < 0.0001); P^2 = 81\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.74)} = 20.97, df = 6 (P < 0.0001); P^2 = 81\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.74)} = 20.97, df = 6 (P < 0.0001); P^2 = 81\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.74)} = 20.97, df = 6 (P < 0.0001); P^2 = 81\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.74)} = 20.97, df = 6 (P < 0.0001); P^2 = 81\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.74)} = 20.97, df = 6 (P < 0.0001); P^2 = 81\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.74)} = 20.97, df = 6 (P < 0.0001); P^2 = 81\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.74)} = 20.97, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.54)} = 20.75, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.54)} = 27.55, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.54)} = 27.55, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.54)} = 27.55, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.54)}{100 (10.28, 57.54)} = 27.57, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.74)}{100 (10.28, 57.54)} = 27.55, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.54)}{100 (10.28, 57.54)} = 27.55, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.54)}{100 (10.28, 57.54)} = 27.55, df = 6 (P < 0.0001); P^2 = 90\% \\ \frac{3300 (10.28, 57.54)}{100 (10.28, 57.54)} = 27.55, df = 6 (P < 0.0001); P^2 = 100, 10.28, 57.53, 2014 \\ \frac{3300 (10.28, 57.54)}{100 (10.28, 57.54)} = 27.53, 10.53, 10.20, 1$	Study or Subaroup						Weight			Year			CI				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $, .						-										
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $																	
$ \begin{array}{ $																	
D Bias 2016 71 10 23 4 101 23.0% 4 151 [2.50, 8.14] 2016 71 2017 33 33 0.74 448.00 (BS.15, 12.3292) 180 2017 Marrouch 2018 113 156 40 174 24.0% 8.80 [5.35, 14.49] 2018 8.80 [5.35, 14.49] 2018 8.80 [5.35, 14.49] 2018 8.80 [5.35, 14.49] 2018 70 40 90 76 40 97. df = $(P < 0.0001)$ 76 4 16 100.0% 33.76 [10.21, 111.65] 70 40 97. df = $(P < 0.0001)$ 76 4 16 $(P < 0.0001)$ 76 4 16 $(P < 0.0001)$ 76 76 4 17 24.9% 8.80 [5.35, 14.49] 2018 70 40 97. df = $(P < 0.0001)$ 76 4 17 24.9% 76 76 76 76 77 76 7 0.0001) 77 77 (P < 0.0001) 70 10 57 45 6 (P < 0.0001) 76 70 10 10 10 20 Control Ablation 70 10 10 10 20 10 6.26 11.74 120 10 10 20 10 6.26 11.74 120 10 10 10 20 10 6.26 11.74 120 10 10 10 10 10 10 10 10 10 10 10 10 10	2 · · · · ·								• • •								
Prablu 2017 33 33 40 33 6.7% 448.90.0 [86.51, 232921.80] 2017 Marrouche 2018 113 156 40 174 24.0% 48.90 [86.51, 232921.80] 2018 Total 69% CD 403 416 100.0% 33.76 [10.21, 111.65] Total events 297 76 Heterogeneity: Tau ² = 1.49; Chi ² = 30.97; df = 6 (P < 0.0001); l ² = 81% (a) Number of patients in sinus rhythm at the end of trials Ablation Control Mean Difference Khan 2008 8 8 41 -1 4 40 15.8% 9.00 [62.6, 11.74] 2008 Maroucha 2011 4.5 11.1 20 2.8 6.7 18 11.58 1.70 [-4.07, 7.47] 2011 Jones 2013 10.9 115 24 5.4 8.5 26 1.168 5.50 [-0.1, 11.14] 2013 Hunter 2014 8.1 5.1 25 -3.6 4.1 23 16.0% 11.70 [0.09, 14.31] 2014 Hunter 2014 8.1 5.1 25 -3.6 4.1 23 16.0% 11.70 [0.09, 14.31] 2014 Hunter 2014 8.1 5.1 25 -3.6 4.1 23 16.0% 50.17.3% 13.90 [7.56, 20.24] 2015 Total (95% CD) 883 385 100.0% 6.80 [3.52, 10.08] Heterogeneily: Tau ² = 15.71; Ch ² = 62.75, df = 6 (P < 0.00001); l ² = 90% Test for overall effect: Z = 4.07 (P < 0.00001) (b) Change in IVEF Study or Subgroup Mean 5D Total Mean 5D Total Weight W. Kandom, 95% CI WR andom, 95% CI								12	• / •				- /				
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$								4480.00					`				
Total (95% C) 403 416 100.0% 33.76 [10.21, 111.65] Total vents 297 76 Heterogeneity: Tau ² = 1.49; Ch ² = 30.97, df = 6 ($P < 0.0001$); $I^2 = 81\%$ (a) Number of patients in sinus rhythm at the end of trials Control Ablation Control Ablation (a) Number of patients in sinus rhythm at the end of trials Control Ablation Control Mean Difference W , Random, 95% Cl Year Wandom , 95% Cl Year W , Random, 95% Cl Ye								4489.00					_ ,				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Marrouche 2018	1.	10 10	0	40	174	24.0%		8.80 [5.55, 14.49]	2018							
Heterogeneity: Tau ² = 1.49; Ch ² = 30.97, df = 6 (P < 0.0001); l ² = 81% Test for overall effect: Z = 5.77 (P < 0.00001) (a) Number of patients in sinus rhythm at the end of trials Study or Subgroup MacDonald 2011 4.5 11.1 20 2.6 6.7 18 1.1.5 20 4.5 4 5.4 8.5 26 1.1.6 33 1.0.9 11.5 24 5.4 8.5 26 1.1.6 33 1.0.7% 1.3.90 (F.5.6, 20.24) 2010 Marouche 2018 Total Mean 5D Total	Total (95% CI)		40	3		416	100.0%	33	3.76 [10.21, 111.65]								
Test for overall effect: $Z = 5.77 (P < 0.00001)$ (a) Number of patients in sinus rhythm at the end of trials (a) Number of patients in sinus rhythm at the end of trials Mean Difference Khan 2008 (b) Control Mean Difference Khan 2008 (c) Kandom, 95% CI Khan 2008 (c) Kandom, 95% CI Khan 2016 (c) Kandom, 95% CI Khan 2016 (c) Kandom, 95% CI Khan 2017 (c) Kandom, 95% CI Khan 2018 (c) Kandom, 95% CI Khan 2017 (c) Kandom, 95% CI Khan 2018 (c) Kandom, 95% CI Khan 2018 (c) Kandom, 95% CI Khan 2016 (c) Kandom, 95% CI Khan 2017 (c) Kandom, 95% CI Khan 2018 (c) Kandom, 95% CI (c) Change in IVEF (c) Change in MLWHFQ (c) Kandom, 95% CI (c) Change in MLWHFQ (c) Kandom, 95%	Total events	29	97		76												
Control Ablation Control Ablation Control Ablation Study or Subgroup Mean SD Total Mean SD Total Mean Difference Wean Difference Khan 2008 8 8 Note of the set of t	Heterogeneity: Tau ²	= 1.49;	Chi ² =	30.97	df = 0	6 (P <	0.0001)	$ I^2 = 819$	6				200				
(a) Number of patients in sinus rhythm at the end of trials Study or Subgroup Mean SD Total Mean Difference Wean Mean Difference <th c<="" td=""><td>Test for overall effect</td><td>t: Z = 5</td><td>.77 (P <</td><td>< 0.00</td><td>001)</td><td></td><td></td><td></td><td></td><td></td><td>0.005</td><td></td><td>0 200</td></th>	<td>Test for overall effect</td> <td>t: Z = 5</td> <td>.77 (P <</td> <td>< 0.00</td> <td>001)</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>0.005</td> <td></td> <td>0 200</td>	Test for overall effect	t: Z = 5	.77 (P <	< 0.00	001)						0.005		0 200			
Ablation Study or Subgroup Mean Mam SD SD Total Mean SD Total SD Mean SD Total SD Mean SD Total V Mean V Mean SSC (1 Vear V Mean Difference V Wean V Mean Difference V Wean SSC (1 MacDonald 2011 4.5 11.1 20 2.8 6.7 18 11.5% 9.00 (6.7, 17.4] 2013 Jones 2013 10.9 15.1 2.5 3.6 1.2 31.06% 5.00 (9.14, 11.4) 2013 J Biase 2016 8.1 4 9.4 6.2 5 83 17.3% 1.30 (7.55, 2.02.2) 2016 Prabhu 2017 18.3 14.5 33 4.4 11.6 33 10.7% 1.30 (7.55, 2.02.2) 2016 Trabhu 2016 7 6.5 146 2 7.5 162 17.1% 5.00 (3.44, 6.56] 2018 Total (95% CI) 383 385 100.0% 6.80 (3.52, 10.08] 4.4 4.0 2.5% -0.00011; I' = 90% -20 -20 -00												Control Ablation					
Study or Subgroup Mean SD Total Wein NR andom, 95% CI Year IV, Random, 95% CI Khan 2008 8 8 41 -1 4 40 15.8% 9.00 [6.26, 11.74] 2008					(a)	Num	ber of p	atients ir	n sinus rhythm at the	end of t	rials						
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $																	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $								-				IV, Random, 95% C					
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$												-	-				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $																	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Jones 2013	10.9) 11.5	24	5.4	4 8.5	26	11.6%	5.50 [-0.14, 11.14]	2013							
Prabhu 2017 18.3 14.5 33 4.4 11.6 33 10.7% 13.90 (7.56, 20.24) 2017 Marrouche 2018 7 6.5 146 2 7.5 162 17.1% 5.00 3.44, 6.56 2018 Total (95% CI) 383 385 10.0% 6.80 [3.52, 10.08] Heterogeneity: Tau ² = 15.71; Chi ² = 62.75, df = 6 (P < 0.0001) Kolono001); l ² = 90% Colspan="4">Colspan="4"Colspan="4">Colspan= 4 <th <="" colspan="4" td=""><td>Hunter 2014</td><td>8.1</td><td>. 5.1</td><td>25</td><td>-3.6</td><td>5 4.1</td><td>23</td><td>16.0%</td><td>11.70 [9.09, 14.31]</td><td>2014</td><td></td><td></td><td></td></th>	<td>Hunter 2014</td> <td>8.1</td> <td>. 5.1</td> <td>25</td> <td>-3.6</td> <td>5 4.1</td> <td>23</td> <td>16.0%</td> <td>11.70 [9.09, 14.31]</td> <td>2014</td> <td></td> <td></td> <td></td>				Hunter 2014	8.1	. 5.1	25	-3.6	5 4.1	23	16.0%	11.70 [9.09, 14.31]	2014			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Di Biase 2016	8.1	. 4	94	6.2	2 5	83	17.3%	1.90 [0.55, 3.25]	2016							
Total (95% Cl) 383 385 100.0% 6.80 [3.52, 10.08] Heterogeneity: Tau ² = 15.71; Chi ² = 62.75, df = 6 (P < 0.00001); I ² = 90% (b) Charge in LVEF Mean SD Total Mean SD Total Mean SD Total Weight NacDonald 2011 -20 -10 0 Mean Difference N. Random, 95% Cl Year Nean Difference Nean Difference N. Random, 95% Cl Mean Difference N. Random, 95% Cl Mean Difference N. Random, 95% Cl Nachonald 2011 -2.9 N. Random, 95% Cl Jone Subgroup Mean SiD Total Mean SD Total Neight Neight N. Random, 95% Cl Mean Difference N. Random, 95% Cl Jone Subgroup	Prabhu 2017	18.3	14.5	33	4.4	11.6	33	10.7%	13.90 [7.56, 20.24]	2017			→				
Heterogeneity: Tau ² = 15.71; Chi ² = 62.75, df = 6 (P < 0.0001); l ² = 90% Test for overall effect: Z = 4.07 (P < 0.0001) (b) Charge in LVEF $\frac{Ablation}{SD Total} \underbrace{Control}{Mean} \underbrace{SD Total}{SD Total} \underbrace{SD Total}{SD Total} \underbrace{SD Total}{SD Total} \underbrace{Mean}{SD Tota} Mean$	Marrouche 2018	7	6.5	146	2	2 7.5	162	17.1%	5.00 [3.44, 6.56]	2018							
Heterogeneity: Tau ² = 15.71; Chi ² = 62.75, df = 6 (P < 0.0001); l ² = 90% Test for overall effect: Z = 4.07 (P < 0.0001) (b) Charge in LVEF $\frac{Ablation}{SD Total} \underbrace{Control}{Mean} \underbrace{SD Total}{SD Total} \underbrace{SD Total}{SD Total} \underbrace{SD Total}{SD Total} \underbrace{Mean}{SD Tota} Mean$	Total (95% CI)			383			385	100.0%	6.80 [3.52, 10.08]								
Test for overall effect: Z = 4.07 (P < 0.0001) 10 20 Control Ablation Test for overall effect: Z = 4.07 (P < 0.0001) Control Mean IVEF Study or Subgroup Mean SD Total Mean SD Total Weight Ny, Random, 95% CI Year Mean Difference Khan 2008 -29 14.4 41 -7 17.8 40 23.8% -22.00 [-29.06, -14.94] 2008 MacDonald 2011 -5.7 19.7 20 -2.8 17.9 18 18.5% -2.90 [-14.85, 9.05] 2011 Jones 2013 -21 29.8 24 -8 29.7 26 14.1% -17.80 [-30.11, -5.49] 2014 Jones 2016 -11 19 94 -6 17 83 25.5% -5.00 [-10.30, 0.30] 2016 Total (95% CI) ZO ZO Total Mean SD Total Mean Mean Macm SD Total Mean Mean SD Total Mean Mean Mean Mean <td></td> <td>- 15 71</td> <td>· Chi² -</td> <td></td> <td></td> <td>6 (P <</td> <td></td> <td></td> <td>. , .</td> <td></td> <td>L</td> <td></td> <td></td>		- 15 71	· Chi ² -			6 (P <			. , .		L						
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	5 ,					0 (F <	0.0000	(1), 1 = 9	/0//0		-20		10 20				
AbilitionControlMeanSDTotalMeanSDTotalWeightWeightWean DifferenceMean DifferenceMean DifferenceNKhan 2008-2914.441-717.84023.8%-22.00 [-29.06, -14.94]2008MacDonald 2011-5.719.720-2.817.91818.5%-2.90 [-14.85, 9.05]2011Jones 2013-2129.824-829.72614.1%-13.00 [-29.51, 3.51]2013Junes 2016-111994-6178325.5%-5.00 [-10.30, 0.30]2016Di Biase 2016-111994-6178325.5%-5.00 [-10.30, 0.30]2016Total (95% CI)20.41-9.0073-12.10 [-20.86, -3.34]-100-50050100Heterogeneity: Tau ² 70.93; Chi ² 17.23, df = 4 (P = 0.002); l ² = 77%rNNNNNNTest for overall effect: Z = 2.71 (P = 0.007)-0.01-0.007-12.10 [-20.86, -3.34]-0.00-100-50050100Khan 20087172.9411656.94016.9%55.00 [26.56, 83.44]2008-100-50NNKhan 20087172.9411656.94016.9%55.00 [26.56, 83.44]2008-100-50NN-0.007Khan 20087172.921.477.418	rest for overall effec		.07 (1 <	0.000	01)							Control Ablation					
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI Year IV, Random, 95% CI Khan 2008 -29 14.4 41 -7 17.8 40 23.8% -22.00 [-29.06, -14.94] 2008 MacDonald 2011 -5.7 19.7 20 -2.8 17.9 18 18.5% -2.90 [-14.85, 9.05] 2011 Jones 2013 -11 19.7 20 -2.8 17.9 18.1% -17.80 [-30.11, -5.49] 2014 Hunter 2014 -18 22 5 -0.2 1.7 83 25.5% -5.00 [-10.30, 0.30] 2016 Total (95% CI) -12 94 -6 17 83 25.5% -5.00 [-10.30, 0.30] 2016 Heterogeneity: Tau ² = 70.93; Chi ² = 17.23, df = 4 (P = 0.002); I ² = 77% 190 100.0% -12.10 [-20.86, -3.34] -100 -50 0 Ablation Control Study or Subgroup Mean SD Total Mean SD Total Mean								(b) Cł	nange in LVEF								
Khan 2008-2914.441-717.84023.8%-22.00[-29.06, -14.94]2008MacDonald 2011-5.719.720-2.817.91818.5%-2.90[-14.85, 9.05]2011Jones 2013-2129.824-829.72614.1%-13.00[-29.51, 3.51]2013Hunter 2014-182225-0.221.52318.1%-17.80[-30.11, -5.49]2014Di Biase 2016-111994-6178325.5%-5.00[-10.30, 0.30]2016Total (95% Cl)204190100.0%-12.10[-20.86, -3.34]Heterogeneity: Tau ² = 70.93; Chi ² = 17.23, df = 4 (P = 0.002); I ² = 77%-100-500Test for overall effect: Z = 2.71 (P = 0.007)CortrolMean DifferenceIV, Random, 95% ClKhan 20087172.9411656.94016.9%55.00 [26.56, 83.44]2008MacDonald 201120.176.52021.477.4189.0%-1.30 [-50.32, 47.72]2011Jones 2013217024-10292616.0%31.00 [0.86, 61.14]2013Di Biase 201622419410378327.0%12.00 [0.51, 23.49]2016Di Biase 201622419410378327.0%12.00 [0.51, 23.49]2016Prabhu 201755168.33329		Ał	olation		Co	ontrol			Mean Difference			Mean Difference					
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Study or Subgroup	Mean	SD T	Total	Mean	SD	۲otal ۱	Veight	IV, Random, 95% C	I Year		IV, Random, 95% C	1				
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Khan 2008	-29	14.4	41	-7	17.8	40	23.8% -	22.00 [-29.06, -14.94	4] 2008							
Hunter 2014 Di Biase 2016 -18 -11 22 25 25 -0.2 21.5 23 23 18.1% -17.80 -17.80 -5.00 $-10.30, 0.30]$ 2014 $-10.30, 0.30]$ Total (95% CI) Heterogeneity: Tau ² = 70.93; Chi ² = 17.23, df = 4 (P = 0.002); l ² = 77% Test for overall effect: Z = 2.71 (P = 0.007) 204 190 100.0% -12.10 -12.10 -12.10 -100 -50 -100 -100 -50 -50 -100 -100 -50 -100 -100 -100 -100 	MacDonald 2011	-5.7	19.7	20	-2.8	17.9	18	18.5%	-2.90 [-14.85, 9.05	5] 2011							
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Jones 2013	-21	29.8	24	-8	29.7	26	14.1%	-13.00 [-29.51, 3.5]	l] 2013							
Total (95% Cl) 204 190 100.0% -12.10 [-20.86, -3.34] Heterogeneity: $Tau^2 = 70.93$; $Chi^2 = 17.23$, $df = 4$ (P = 0.002); $l^2 = 77\%$ -100 -50 0 50 100 Control Mean Difference Mean Difference Mean Difference Number of the second of the	Hunter 2014	-18	22	25	-0.2	21.5	23	18.1%	-17.80 [-30.11, -5.49	9] 2014							
Heterogeneity: $Tau^2 = 70.93$; $Chi^2 = 17.23$, $df = 4$ (P = 0.002); $I^2 = 77\%$ Test for overall effect: Z = 2.71 (P = 0.007) (c) Change in MLWHFQ Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean Difference Study or Subgroup Mean SD Total Mean Difference Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 Mean Difference IV, Random, 95% CI Year Mean Difference IV, Random, 95% CI Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.86, 61.14] 2013 Image: Colspan="4" Jones 2016 22 4 10 27.0% 12.00 [0.51, 23.49]	Di Biase 2016	-11	19	94	-6	17	83	25.5%	-5.00 [-10.30, 0.30	0] 2016		-=-					
Heterogeneity: $Tau^2 = 70.93$; $Chi^2 = 17.23$, $df = 4$ (P = 0.002); $I^2 = 77\%$ Test for overall effect: Z = 2.71 (P = 0.007) (c) Change in MLWHFQ Mean Difference Mean Difference Study or Subgroup Mean SD Total Mean Difference Study or Subgroup Mean SD Total Mean Difference Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 Mean Difference IV, Random, 95% CI Year Mean Difference IV, Random, 95% CI Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 Mean Difference IV, Random, 95% CI Jones 2013 21 70 24 10 <	Total (95% CI)			204			190 1	00.0%	-12.10 [-20.863.34	1							
-100 -50 50 100 Test for overall effect: Z = 2.71 (P = 0.007) Study or Subgroup -100 -50 0 50 100 Ablation Control (c) Change in MLWHFQ Mean Difference IV, Random, 95% CI Year IV, Random, 95% CI Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 IV, Random, 95% CI MacDonald 2011 20.1 76.5 20 21.4 77.4 18 9.0% -1.30 [-50.32, 47.72] 2011 Image: Colspan="6">IV, Random, 95% CI Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.51, 23.49] 2016 Image: Colspan="6">Image: Colspan="6"Colspan="6" Image: Colspan="6		= 70 93.	Chi ² –		df – 4	l (P – ∩					—	—					
Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.86, 61.14] 2013 Di Biase 2016 22 41 10 37 83 27.0% 12.00						r (r = 0	.002), 1	- ///0			-100		50 100				
Ablation Control Mean Difference Mean Difference IV, Random, 95% CI Year IV, Random, 95% CI Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI Year IV, Random, 95% CI Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 MacDonald 2011 20.1 76.5 20 21.4 77.4 18 9.0% -1.30 [-50.32, 47.72] 2011	rest for overall effect	2 – 2.	1 (r –	0.007)								Ablation Control					
Study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI Year IV, Random, 95% CI Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 MacDonald 2011 20.1 76.5 20 21.4 77.4 18 9.0% -1.30 [-50.32, 47.72] 2011 Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.86, 61.14] 2013 Di Biase 2016 22 41 94 10 37 83 27.0% 12.00 [0.51, 23.49] 2016 Prabhu 2017 55 168.3 33 29 17.7 33 3.8% 26.00 [-57.50, 109.50] 2017								(c) Chan	ige in MLWHFQ								
Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 MacDonald 2011 20.1 76.5 20 21.4 77.4 18 9.0% -1.30 [-50.32, 47.72] 2011 Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.86, 61.14] 2013 Di Biase 2016 22 41 94 10 37 83 27.0% 12.00 [0.51, 23.49] 2016 Prabhu 2017 55 168.3 33 29 177.7 33 3.8% 26.00 [-57.50, 109.50] 2017		А	blation		c	Control			Mean Difference			Mean Difference					
Khan 2008 71 72.9 41 16 56.9 40 16.9% 55.00 [26.56, 83.44] 2008 MacDonald 2011 20.1 76.5 20 21.4 77.4 18 9.0% -1.30 [-50.32, 47.72] 2011 Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.86, 61.14] 2013 Di Biase 2016 22 41 94 10 37 83 27.0% 12.00 [0.51, 23.49] 2016 Prabhu 2017 55 168.3 33 29 177.7 33 3.8% 26.00 [-57.50, 109.50] 2017	Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95%	CI Yea	r	IV, Random, 95% C	1				
MacDonald 2011 20.1 76.5 20 21.4 77.4 18 9.0% -1.30 [-50.32, 47.72] 2011 Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.86, 61.14] 2013 Di Biase 2016 22 41 94 10 37 83 27.0% 12.00 [0.51, 23.49] 2016 Prabhu 2017 55 168.3 33 29 177.7 33 3.8% 26.00 [-57.50, 109.50] 2017		71	72.9	41	16	56.9		-									
Jones 2013 21 70 24 -10 29 26 16.0% 31.00 [0.86, 61.14] 2013 Di Biase 2016 22 41 94 10 37 83 27.0% 12.00 [0.51, 23.49] 2016 Prabhu 2017 55 168.3 33 29 177.7 33 3.8% 26.00 [-57.50, 109.50] 2017	MacDonald 2011																
Di Biase 2016 22 41 94 10 37 83 27.0% 12.00 [0.51, 23.49] 2016 Prabhu 2017 55 168.3 33 29 177.7 33 3.8% 26.00 [-57.50, 109.50] 2017										-							
	-	22	41	94	10					-							
Marrouche 2018 41 47.5 139 1 47.5 155 27.3% 40.00 [29.12, 50.88] 2018	Prabhu 2017	55	168.3	33	29	177.7	' 33	3.8%	26.00 [-57.50, 109.5	0] 2013	7						
	Marrouche 2018	41	47.5	139	1	47.5	155	27.3%	40.00 [29.12, 50.8	8] 2018	8	-	-				





(d) Change in 6-minute walk distance

-100

-50

100

50


0 Control Ablation

	Ablati	on	Conti	ol		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	r M-H, Random, 95% CI
Khan 2008	0	41	0	40		Not estimable	2008	8
MacDonald 2011	0	20	0	18		Not estimable	2011	1
Jones 2013	1	25	0	26	2.0%	3.24 [0.13, 83.47]	2013	3
Hunter 2014	0	26	1	24	2.0%	0.30 [0.01, 7.61]	2014	4
Di Biase 2016	8	102	18	101	26.8%	0.39 [0.16, 0.95]	2016	6
Prabhu 2017	0	33	0	33		Not estimable	2017	7
Marrouche 2018	24	156	46	174	69.2%	0.51 [0.29, 0.88]	2018	8 -
Total (95% CI)		403		416	100.0%	0.49 [0.31, 0.77]		•
Total events	33		65					
Heterogeneity: Tau ² = Test for overall effect	,		,	3 (P =	0.65); l ² =	= 0%		0.01 0.1 1 10 100 Ablation Control

(e) All-cause mortality

8

FIGURE 2: Continued.



(f) HF-related hospitalizations

FIGURE 2: Change in outcomes, all-cause mortality, and HF-related hospitalizations.

	Khan (N = 41)	MacDonald (N = 21)	Jones (N = 25)	Hunter $(N = 26)$	Di Biase (N = 102)	Prabhu (N = 33)	Marrouch (N = 151)	Total (N=399)
Death, N (%)	0	0	0	0	0	0	0	0
	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)
Stroke, N (%)	0	1	0	1	0	0	0	2
	(0.0%)	(4.8%)	(0.0%)	(3.8%)	(0.0%)	(0.0%)	(0.0%)	(0.5%)
Cardiac tamponade, N (%)	0	2	1	1	0	0	0	4
	(0.0%)	(9.5%)	(4.0%)	(3.8%)	(0.0%)	(0.0%)	(0.0%)	(1.0%)
Pericardial effusion, N (%)	1	0	0	0	1	0	3	5
	(2.4%)	(0.0%)	(0.0%)	(0.0%)	(1.0%)	(0.0%)	(2.0%)	(1.3%)
Pulmonary vein stenosis,	2	0	0	0	0	0	1	3 (0.8%)
N (%)	(4.9%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.7%)	
Access site complications,	3	0	1	0	2	1	6	13
N (%)	(7.3%)	(0.0%)	(4.0%)	(0.0%)	(2.0%)	(3.0%)	(4.0%)	(3.3%)
Heart failure	1	3	1	0	0	0	1	6
exacerbation, N (%)	(2.4%)	(14.3%)	(4.0%)	(0.0%)	(0.0%)	(0.0%)	(0.7%)	(1.5%)

TABLE 5: Complications related to catheter ablation.

It would be difficult to compare the rate of adverse events between medical therapy and catheter ablation, as studies allowed patients to remain on rate and/or rhythm control agents post ablation.

4. Discussion

This systematic review and meta-analysis of AF ablation in patients with existing heart failure identified seven RCTs. Specifically, one study compared AF ablation to AV nodal ablation with biventricular pacing as a rate control strategy [7], four studies compared AF catheter ablation to rate control using medical therapy [2, 3, 8, 10], one study compared AF ablation to amiodarone [9], and one study compared AF ablation to the combination of rate and rhythm control [11].

Summary evidence from the seven included RCTs showed that AF catheter ablation is associated with a statistically significant increase in LVEF, MLWHFQ, and 6MWT distance, with mean differences of 6.8%, -12.1, and 29.3, respectively. Although there is significant heterogeneity, the treatment effect did not change with sensitivity testing. These results in particular are not different than the meta-analysis performed by Al-Halabi et. al. [13], which included four RCTs. The increase in LVEF is also consistent with a meta-analysis of observational studies [14].

The improvement in LVEF and 6MWT distance provides objective evidence for the benefit of AF ablation in patients

with systolic HF. Whether this translates to a net benefit in the hard primary endpoints such as reduction in heart failure hospitalizations and mortality is not yet well-established. In our analysis, we noticed significant reduction in all-cause mortality in the AF ablation arm (OR 0.49; 95% CI: 0.31 – 0.77; P = 0.002). Despite this reduction, our confidence in this outcome is low since only the CASTLE AF trial [11] was designed to evaluate this outcome. HF-related hospitalizations were evaluated in the AATAC and CASTLE AF trials, and were significantly lower in the ablation arm (26.7% vs. 45.1%, OR 0.43; 95% CI: 0.29 – 0.64; P< 0.001). Nonetheless, lack of blinding may have led to potential bias in the outcome assessment.

The majority of patients in the trials had persistent AF (80.1%) and had NYHA functional class of II-III, thus limiting the ability to generalize the results. Namely, the results may not be extrapolated to patients with paroxysmal AF or those with asymptomatic (NYHA I) or severe (NYHA IV) functional classification. Regardless, our results show that in patients with persistent AF, where rate control is often committed, a rhythm control strategy using AF ablation as a tool might be beneficial.

Complications related to AF ablation although not common are also not rare. In the present meta-analysis, the overall complication rate was 33 (8.3%). About two-thirds of the complications were driven by stroke, cardiac tamponade, pericardial effusion, pulmonary venous stenosis and heart failure exacerbations. This rate of complications is higher than what is reported in a large cohort study (5.2%) [15] and a meta-analysis of 83,236 patients (2.9%) [16]. The higher rate of complications in our study may be explained by the structurally abnormal hearts in the population examined, and should be taken in consideration when referring such patients to AF ablation.

5. Conclusions

In patients with AF and coexisting HF, an ablation strategy results in improved LV function, functional capacity, and quality of life. This benefit might translate into improvement in hard outcomes, but more studies are needed to validate this idea. Overall, data from the present meta-analysis support the use of AF ablation in selected patients with HF.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

- R. Santhanakrishnan, N. Wang, M. G. Larson et al., "Atrial fibrillation begets heart failure and vice versa: Temporal associations and differences in preserved versus reduced ejection fraction," *Circulation*, vol. 133, no. 5, pp. 484–492, 2016.
- [2] M. R. MacDonald, D. T. Connelly, N. M. Hawkins et al., "Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: A randomised controlled trial," *Heart*, vol. 97, no. 9, pp. 740–747, 2011.
- [3] D. G. Jones, S. K. Haldar, W. Hussain et al., "A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure," *Journal of the American College of Cardiology*, vol. 61, no. 18, pp. 1894–1903, 2013.
- [4] D. L. Dries, D. V. Exner, B. J. Gersh, M. J. Domanski, M. A. Waclawiw, and L. W. Stevenson, "Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials," *Journal of the American College of Cardiology*, vol. 32, no. 3, pp. 695–703, 1998.
- [5] D. D. McManus, G. Hsu, S. H. Sung et al., "Atrial fibrillation and outcomes in heart failure with preserved versus reduced left ventricular ejection fraction.," *Journal of the American Heart Association*, vol. 2, no. 1, p. e005694, 2013.
- [6] D. Roy, M. Talajic, S. Nattel et al., "Rhythm control versus rate control for atrial fibrillation and heart failure," *The New England Journal of Medicine*, vol. 358, no. 25, pp. 2667–2677, 2008.
- [7] M. N. Khan, P. Jaïs, J. Cummings et al., "Pulmonary-vein isolation for atrial fibrillation in patients with heart failure," *The New England Journal of Medicine*, vol. 359, no. 17, pp. 1778–1785, 2008.
- [8] R. J. Hunter, T. J. Berriman, I. Diab et al., "A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial)," *Circulation: Arrhythmia and Electrophysiology*, vol. 7, no. 1, pp. 31–38, 2014.

- [9] L. Di Biase, P. Mohanty, S. Mohanty et al., "Ablation Versus Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC Multicenter Randomized Trial," *Circulation*, vol. 133, no. 17, pp. 1637–1644, 2016.
- [10] S. Prabhu, A. J. Taylor, B. T. Costello et al., "Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study," *Journal of the American College of Cardiology*, vol. 70, no. 16, pp. 1949–1961, 2017.
- [11] N. F. Marrouche, J. Brachmann, D. Andresen et al., "Catheter ablation for atrial fibrillation with heart failure," *The New England Journal of Medicine*, vol. 378, no. 5, pp. 417–427, 2018.
- [12] A. Liberati, D. G. Altman, J. Tetzlaff et al., "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration," *PLoS Medicine*, vol. 6, no. 7, Article ID e1000100, 2009.
- [13] S. Al Halabi, M. Qintar, A. Hussein et al., "Catheter ablation for atrial fibrillation in heart failure patients: A meta-analysis of randomized, controlled trials," *JACC: Clinical Electrophysiology*, vol. 1, no. 3, pp. 200–209, 2015.
- [14] S. B. Wilton, A. Fundytus, W. A. Ghali et al., "Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction," *American Journal of Cardiology*, vol. 106, no. 9, pp. 1284–1291, 2010.
- [15] M. Bohnen, W. G. Stevenson, U. B. Tedrow et al., "Incidence and predictors of major complications from contemporary catheter ablation to treat cardiac arrhythmias," *Heart Rhythm*, vol. 8, no. 11, pp. 1661–1666, 2011.
- [16] A. Gupta, T. Perera, A. Ganesan et al., "Complications of catheter ablation of atrial fibrillation a systematic review," *Circulation: Arrhythmia and Electrophysiology*, vol. 6, no. 6, pp. 1082–1088, 2013.



The Scientific World Journal

Journal of Immunology Research



Research and Practice











BioMed Research International



Journal of Ophthalmology



Computational and Mathematical Methods in Medicine



International



Behavioural Neurology



Evidence-Based Complementary and Alternative Medicine







Research and Treatment





Oxidative Medicine and Cellular Longevity



Submit your manuscripts at www.hindawi.com